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Abstract
Introduction: Genome-wide association study meta-analyses have robustly implicated three loci 
that affect susceptibility for smoking: CHRNA5\CHRNA3\CHRNB4, CHRNB3\CHRNA6 and EGLN2\
CYP2A6. Functional follow-up studies of these loci are needed to provide insight into biological 
mechanisms. However, these efforts have been hampered by a lack of knowledge about the spe-
cific causal variant(s) involved. In this study, we prioritized variants in terms of the likelihood they 
account for the reported associations.
Methods: We employed targeted capture of the CHRNA5\CHRNA3\CHRNB4, CHRNB3\CHRNA6, 
and EGLN2\CYP2A6 loci and flanking regions followed by next-generation deep sequencing (mean 
coverage 78×) to capture genomic variation in 363 individuals. We performed single locus tests to 
determine if any single variant accounts for the association, and examined if sets of (rare) variants 
that overlapped with biologically meaningful annotations account for the associations.
Results: In total, we investigated 963 variants, of which 71.1% were rare (minor allele frequency 
< 0.01), 6.02% were insertion/deletions, and 51.7% were catalogued in dbSNP141. The single 
variant results showed that no variant fully accounts for the association in any region. In the 
variant set results, CHRNB4 accounts for most of the signal with significant sets consisting 
of directly damaging variants. CHRNA6 explains most of the signal in the CHRNB3\CHRNA6 
locus with significant sets indicating a regulatory role for CHRNA6. Significant sets in CYP2A6 
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involved directly damaging variants while the significant variant sets suggested a regulatory 
role for EGLN2.
Conclusions: We found that multiple variants implicating multiple processes explain the signal. 
Some variants can be prioritized for functional follow-up.
Introduction
Genome-wide association study meta-analyses, together comprising 
over 150 000 subjects,1–4 have robustly implicated three loci that 
affect susceptibility for smoking behavior in subjects with European 
ancestry. These loci are: CHRNA5\A3\B4 on chromosome 15, 
CHRNB3\A6 on chromosome 8, and EGLN2\CYP2A6 on chro-
mosome 19. Functional follow-up studies of these loci are needed 
to provide insight into the biological mechanisms. However, these 
efforts have been hampered by a lack of knowledge about the spe-
cific causal variants involved. The goal of this article is to identify the 
variants likely to account for the previously detected associations in 
these loci. Given the robustness of these findings, we assume that a 
complete enumeration of all variants at each locus will likely con-
tain the causal variants and our analyses can therefore be directed at 
prioritizing (sets of) variants based on statistical and bioinformatic 
evidence.
To achieve our goal, we employ targeted capture5 of these loci in 
combination with deep, massively-parallel next-generation sequenc-
ing.6 This approach is similar to exome sequencing,7 but instead of 
capturing only exons, we capture the entire gene and their flanking 
regions. This method can identify all rare, low-frequency, and com-
mon single nucleotide polymorphisms (SNPs) plus small insertion/
deletions. Our prioritization analyses examine whether a single com-
mon or low-frequency variant accounts for the association signal 
or if multiple (rare) variants are involved. In addition, by grouping 
variants in terms of biological function (eg, likely to affect regula-
tory function or protein coding) we can examine whether a single or 
multiple mechanisms are involved, which in turn allows us to begin 
generating functional hypotheses.
Methods
Sample and Measures
The data for this study come from the Virginia Twin Study on 
Adolescent and Behavioral Development (VTSABD8). A total of 363 
independent individuals were included in the sequenced sample (ie, 
including only one twin from a twin pair). The sequenced sample 
was 38.8% male, 53.7% from a monozygotic twin pair, and 71.9% 
reported ever using a form of tobacco in their lifetime. The study 
was limited to subjects of European ancestry as insufficient num-
bers from other ancestry groups were available. Blood samples were 
collected when subjects were aged 25 to 34 from which DNA was 
extracted. All procedures were approved by ethical committees, and 
all subjects provided informed consent.
To be consistent with previous genome-wide association study 
meta-analyses that implicated the loci under consideration,1–4 the 
phenotype used in this study is smoking quantity as measured by 
the number of cigarettes smoked per day. This is a prospective 
measure of the amount smoked per day over adolescence and early 
adulthood. For a further discussion of the phenotype, please see the 
Supplementary Material and Supplementary Table S1.
Sequencing
We used the solution-based hybridization targeted capture technol-
ogy (SureSelectXT, Agilent) to target entire genes and ±5kb of their 
flanking regions. In this method, a library of synthetic oligonucleo-
tides (baits) complementary to the sequence of interest is custom 
designed and manufactured.5 These baits are then used to extract the 
desired genomic regions from fragmented genomic DNA samples. 
Library design and bait tiling were carried out using Agilent eAr-
ray. After removing overlap and collapsing neighboring genes into 
single loci, repetitive elements were removed as they can be difficult 
to align.
The libraries were paired-end sequenced (75bp + 35bp 
reads) on the SOLiD 5500xl (Life Technologies). The sequenced 
reads were aligned to the human genome (hg19/GRCh37) using 
Bioscope 1.3 (Life Technologies) that aligns in color-space and 
takes advantage of the increased ability of the SOLiD two-base 
encoding to identify sequencing errors. After alignment, quality 
control measures were implemented including dropping subjects 
with low mapped reads (<1 million) and fold enrichment (<365). 
Mean coverage across the targeted regions was 78×, with at least 
10×/20× coverage for 95.4%/90.1% of the targeted regions, an 
average fold enrichment of 393.8, and 97.9% of baits covered. 
This level of coverage is very high for color space data, where 
two color call errors must occur by chance at the same position 
before a SNP is incorrectly called and therefore should result in 
fewer base calling errors relative to equivalent coverage on other 
sequencing platforms.6
Variant Calling and Annotation
The variants were called using GATK9 using standard hard filter-
ing parameters and variant quality score recalibration according to 
GATK Best Practices recommendations.10,11 We defined rare variants 
as having a minor allele frequency < 0.01, low-frequency variants 
as 0.01 ≤ minor allele frequency < 0.05, and common variants as 
minor allele frequency ≥ 0.05. Singleton variants where the minor 
allele was found in one person were removed from the following 
analyses.
All variants passing quality control were annotated to exam-
ine if variants overlapped with bioinformatic features from the 
following databases: UCSC Genome Browser and GENCODE. 
Details are provided in Supplementary Table S2. To determine 
their novelty, identified variants were compared with dbSNP 
(v14112) and the 1000 Genomes Database13 (1KG). Variants were 
also annotated for overlap with 15 chromatin states in brain tis-
sue from the Anterior Caudate, Hippocampus, Mid-frontal Lobe, 
and Substantia Nigra regions, which are all known to be involved 
with nicotine addiction. See Supplementary Material for a descrip-
tion of the chromatin states and how they were generated by the 
Roadmap Epigenomics Project.14 Annotations were used to pri-
oritize variants and to form variant sets for the SNP set-based 
association tests.
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Statistical Analyses
To prioritize (sets of) variants in terms of the likelihood they 
account for the reported associations, we used results from the tests 
described below.
Individual Variants
We performed single locus tests on all common and low-frequency 
variants passing quality control filters using a linear regression 
model of additive effects in PLINK.15 Sex and 10 ancestry principal 
components (see Supplementary Material for a description of the 
principal component analysis) were included as covariates to control 
for sex differences and ancestry. Variants were then prioritized based 
on their effect size as measured by R2, the square of the coefficient 
of multiple correlation, where R2 ≥ 0.25 is a large effect, 0.25 > R2 ≥ 
0.09 is a medium effect, 0.09 > R2 ≥ 0.01 is a small effect, and R2 < 
0.01 is little to no effect.16
Sets of Variants
SNP set-based association tests were performed using SKAT17 to pri-
oritize sets of variants that may influence smoking. Specifically, we 
examined if biologically functional annotations (for a full list of anno-
tations see Supplementary Table S2), such as variants that cause a dam-
aging amino acid change as predicted by SIFT18 and/or PolyPhen2,19 
for example, could account for the association signal with smoking. 
As in the single locus analysis, sex and 10 principal components were 
included as covariates. Since SKAT is meant to test association of sets 
of variants, and not estimate the effect size of a set,20 the sets of vari-
ants were prioritized based on their P value. Through examining the 
types of variants sets that are significantly associated with smoking, 
we can begin to generate hypotheses about the potential mechanism 
through which these variants may influence smoking.
Results
Variant Calling
We identified 385 variants in the CHRNA5\A3\B4 region 
(chr15:78,852,861-78,938,587) of which 279 (72.5%) were rare, 31 
(8.05%) were insertion/deletions, 210 (54.5%) were catalogued in 
dbSNP141, 160 (41.6%) were in 1KG, and 115 (29.8%) were sin-
gletons. The CHRNB3\A6 region (chr15:78,852,861-78,938,587) 
had 280 variants, of which 188 (67.1%) were rare, 12 (4.29%) were 
insertion/deletions, 157 (56.0%) were catalogued in dbSNP141, 130 
(46.4%) were in 1KG, and 76 (27.1%) were singletons. There were 
298 variants in the region of EGLN2\CY2A6 (chr8:42,547,561-
42,628,929) of which 218 (73.2%) were rare, 15 (5.03%) were 
insertion/deletions, 131 (43.9%) were catalogued in dbSNP141, 115 
(38.6%) were in 1KG and 80 (26.9%) were singletons. For a complete 
list of variants and their annotations see Supplementary Table S3.
Individual Variants
The results of the single variant prioritization are shown in Table 1. 
In CHRNB3\A6 and EGLN2\CYP2A6, there were only a few vari-
ants with R2 > 0.01 while CHRNA5\A3\B4 had many variants with 
R2 > 0.01. However, none of the investigated loci had an individual 
variant with a large effect size. This suggests that, rather than a single 
variant with a large effect size, the previous genome-wide associa-
tion study signals found in each region may have been caused by a 
variant we could not identify or by multiple variants with smaller 
effect sizes.
Sets of Variants
We investigated whether sets of all variants and only rare variants 
that overlapped with a biologically meaningful annotation were 
associated with smoking and could therefore potentially account for 
the previous association signals. The results with P value < .05 for 
each loci are shown in Table 2 and considered below.
CHRNA5\A3\B4
CHRNA5 had significant sets in evolutionarily conserved regions and 
repressed polycomb proteins, which have been shown to repress gene 
expression,21 in three of the four brain regions. CHRNB4 had nine sig-
nificant sets that tended to be combinations of rare and non-rare sets. 
These sets included variants that can cause potentially damaging amino 
acid changes and heterochromatin, which is known to be involved in 
regulating gene expression.22 These results suggest that significant sets 
of variants in CHRNA5 and CHRNB4 may have regulatory potential 
for smoking quantity. CHRNA3 had no significant associations.
CHRNB3\A6
CHRNA6 had several significant sets of variants. The rare sets 
included missense variants, while the all-variant sets were related 
to repressed polycomb proteins. This suggests that significant vari-
ants sets in CHRNA6 may have regulatory potential for smoking. 
CHRNB3 had no significant set tests.
EGLN2\CYP2A6
Both CYP2A6 and EGLN2 had sets of variants overlapping with 
biologically meaningful annotations that were significantly associ-
ated with smoking. The significant sets in CYP2A6 were variants that 
could potentially affect protein coding and chromatin states involved 
with the enhancement of transcription. The significant sets in EGLN2 
tended to be from rare variant sets with regulatory annotations like 
gene promoters, and chromatin states involving or flanking active 
transcription start sites. These results suggest that significant variants 
sets in CYP2A6 may affect protein coding, while significant variant 
sets in EGLN2 may have functional regulatory role.
Discussion
We prioritized variants in three loci known to be associated with 
smoking in order to identify variants that are likely to account for 
the association. The single variant results showed that no single com-
mon or low-frequency variant with a large effect size could fully 
explain the previous associations in any of the loci. There were, 
however, multiple variants with smaller effect sizes in each region 
that could account for some of the signal. This result is similar to 
what was seen in genome-wide association studies of smoking where 
variant(s) were found to be associated, but not to have a large effect 
size.23 When considering sets of variants, we found evidence for over-
lap with potentially functional (affecting protein coding or regula-
tory) annotations. In CHRNA5\A3\B4, CHRNB4 accounts for most 
of the signal with some significant sets consisting of damaging vari-
ants (ie, missense, POLYPHEN deleterious, and SIFT damaging) and 
variants that overlapped with heterochromatin. CHRNA6 explains 
most of the signal in the CHRNB3\A6 locus with significant sets 
indicating a potentially regulatory role for CHRNA6. Both CYP2A6 
and EGLN2 could account for the association in that region, but 
through different processes. That is, the sets in CYP2A6 tended to 
involve variants that may affect amino acid sequence in the encoded 
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protein, while the significant rare variant sets suggested regulatory 
processes could underpin the association with EGLN2.
Several previous studies have sequenced the loci considered 
here, with multiple investigations having sequenced the CHRNA5\
A3\B4 and CHRNB3\A6 loci as part of larger studies focusing on 
all cholinergic receptors with the goal of identifying causal vari-
ants for smoking.24–28 These studies come to similar conclusions: 
that it is not a single variant acting alone that is causal, but rather 
sets of variants.24,25,28 The sets they identified are rare variants that 
overlap with functional annotations such being missense or non-
synonymous variants. Several of these previous studies focused 
only on exons,24–26,29 and therefore would have missed 22 out of 27 
(81.5%) of the single locus top findings and 23 out of 33 (69.6%) 
variant set top findings. To our knowledge, none of these previous 
investigations examined the role regulatory variant sets may play 
in smoking.
Our findings must be interpreted in the context of the potential 
limitations. A potential limitation is the statistical power for detecting 
sets of variants associated with smoking quantity with our modest 
sample size of 363. Using SKAT,17 we conducted a small power study 
(see Supplementary Material for description and Supplementary 
Table S4 for results), which showed that only in a few extreme cases 
we would not have enough power to detect association with sets of 
variants. Additionally, given the strong prior associations of these 
regions with smoking, having enough power is less of an issue given 
that the goal is to prioritize variants that are already known to have 
an association. Another limitation is that our results suggest poten-
tial mechanisms through which the prioritized variants may affect 
smoking, rather than proving the mechanism. Possible next steps 
to do this include prioritization of these variants in an independ-
ent sample and examining the function of significant sets in targeted 
laboratory experiments. Potential methods include targeted genome 
Table 1. Common and Low-Frequency Variant Single Locus Results With R2 ≥ 0.010 by Loci
PSN(bp) Gene SNV number RA AA AAF EFF P R2 Features
CHRNA5\A3\B4
 78892784 CHRNA3 rs62010327 G A 0.373 − .002 0.026 Intron, Shore
 78897865 CHRNA3 rs75104798 C CT 0.321 − .004 0.023 Intron
 78894971 CHRNA3 rs62010328 C T 0.365 − .005 0.022 Intron, Shore
 78872211 CHRNA5 TCTTC T 0.014 + .006 0.021 Intron
 78885988 CHRNA5 rs615470 T C 0.623 − .006 0.021 Exon
 78909539 CHRNA5 rs3743073 G T 0.623 − .006 0.021 Intron, TFBScons
 78881618 CHRNA5 rs17408276 T C 0.375 − .006 0.021 Intron
 78887832 CHRNA3 rs660652 A G 0.626 − 0.021 Exon
 78869930 CHRNA5 rs495956 C T 0.622 − .007 0.020 Intron
 78865694 CHRNA5 rs61012457 C G 0.374 − .010 0.018 Intron, TFBScons
 78876505 CHRNA5 rs692780 C G 0.626 − .011 0.018 Intron
 78856266 rs3829787 C T 0.369 − .014 0.017 Promoter(CHRNA5), 
Shore, TFBScons
 78890321 CHRNA3 rs6495307 C T 0.428 − .021 0.015 Intron, TFBScons
 78894896 CHRNA3 rs3743077 C T 0.424 − .021 0.015 Intron, Shore, TFBScons
 78911780 CHRNA3 rs2067808 G A 0.379 − .022 0.015 Intron, Shore, DNase
 78858491 CHRNA5 rs871058 G A 0.355 − .022 0.015 Intron, Shore, DNase
 78884227 CHRNA5 rs514743 T A 0.625 − .030 0.013 Intron
 78869579 CHRNA5 rs601079 T A 0.572 − .031 0.013 Intron
 78871288 CHRNA5 rs386605197 T C 0.572 − .031 0.013 Intron
 78865893 CHRNA5 rs6495306 G A 0.573 − .033 0.013 Intron
 78907997 CHRNA3 rs11418931 A AT 0.120 + .034 0.012 Intron, TFBScons
 78910267 CHRNA3 rs28669908 C A 0.215 + .050 0.011 Intron, Shore, DNase, 
TFBScons
 78930510 CHRNB4 rs111358583 A G 0.759 + .057 0.010 Intron
CHRNB3\A6
 42598544 rs77112867 T C 0.039 + .018 0.016
 42563175 CHRNB3 rs4737066 A G 0.966 + .039 0.019 Intron
EGLN2\CYP2A6
 41316746 rs11668644 G C 0.535 − .022 0.019 Island, DNase, 
TFBScons, SuperDup
 41349172 rs28742185 T C 0.709 − .041 0.012 SuperDup
 41304074 rs117576995 G A 0.011 + .054 0.010 Promoter(EGLN2), 
Shore, DNase, 
TFBScons
AA = alternate allele; AAF = alternate allele frequency; PSN = position; RA = reference allele; SNV = single nucleotide variant. EFF is the direction of the effect 
of alternate allele where a “+” indicates smoking quantity is positively associated with alternate allele count and a “−” indicates smoking quantity is negatively 
associated with alternate allele count. “Feature” describes genomic attributes overlapping with the SNV’s coordinates. “Exon” and “Intron” designate overlap with 
RefSeq genes; “DNase” indicates a genomic region hypersensitive to DNasel; “Promoter” indicates the SNV is within 5kb of a transcription start site with the 
name of the gene it is promoting in parentheses; “CGI” denotes overlap with a CpG Island; “Shore” is ±2kb flanking a CGI; “SuperDup” designates overlap with 
a genomic super duplication; “TFBSCons” indicates SNV is within 100bp of a conserved transcription factor recognition sequence in mammals (TRANSFAC).
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editing where DNA is changed using artificially engineered nucleases 
and the effect is observed,30 or targeted chromatin immunoprecipita-
tion assays of regulatory elements such as transcription factor bind-
ing sites and histone marks overlapping with the significant results.
In conclusion, we found that it is unlikely that a single com-
mon or low-frequency variant accounts for the entire association 
signal in any of the three smoking susceptibility loci considered. 
We identified specific genes within loci and specific sets of variants 
within those genes. This suggests it is likely that multiple variants 
and multiple processes are driving the association signal. We found 
interesting protein coding variant sets, however they do not account 
for all signals and it is likely that other variants also contribute via 
a regulatory role.
URLs
 Agilent eArray: https://earray.chem.agilent.com/earray/
 GENCODE: www.gencodegenes.org
 UCSC Genome Browser: http://genome.ucsc.edu
Table 2. Genomic Feature Set Results With P Value < .05
Gene Feature All P value Rare P value All vars. Rare vars.
CHRNA3/CRNA5/CHRNB4
 CHRNB4 Heterochromatin—AC, HM, SN 4.71E-07 .017 4 1
 CHRNB4 Heterochromatin—MFL 1.02E-04 .141 8 3
 CHRNB4 Non Coding RNA .009 .018 6 5
 CHRNA5 Repressed PolyComb—SN .012 .042 29 20
 CHRNB4 Missense .027 .034 6 3
 CHRNB4 POLYPHEN—Deleterious .036 .019 6 4
 CHRNA5 Repressed PolyComb—MFL .037 .228 50 34
 CHRNA5 Repressed PolyComb—AC .038 .495 35 25
 CHRNB4 Conserved .043 .015 6 3
 CHRNA5 Conserved .044 .052 3 1
 CHRNB4 TFBS .048 .082 2 2
 CHRNB4 SIFT—Damaging .054 .011 8 4
 CHRNB4 Exon .076 .023 13 7
CHRNB3/CHRNA6
 CHRNA6 Missense 1.75E-07 2.79E-07 5 5
 CHRNA6 Conserved 5.57E-07 1.34E-06 10 10
 CHRNA6 Exon 9.42E-05 2.69E-06 12 11
 CHRNA6 Repressed PolyComb—HM .002 .418 43 24
 CHRNA6 Repressed PolyComb—AC .030 .562 61 33
 CHRNA6 Repressed PolyComb—SN .067 .019 8 6
CYP2A6/EGLN2
 CYP2A6 Enhancer—HM 3.01E-04 .161 3 1
 CYP2A6 Synonymous .002 .037 10 5
 CYP2A6 POLYPHEN—Deleterious .003 .003 6 3
 CYP2A6 SIFT—Damaging .003 .005 8 4
 CYP2A6 Exon .016 .108 21 11
 CYP2A6 Shore .025 .153 30 19
 EGLN2 Flank Active TSS—AC .020 .006 14 7
 EGLN2 Promoter .033 .019 6 5
 EGLN2 Enhancer—SN .042 .390 36 17
 EGLN2 Active TSS—HM .073 .032 24 12
 EGLN2 Active TSS—SN .076 .039 25 13
 EGLN2 Active TSS—MFL .127 .011 34 19
 EGLN2 Flank Active TSS—SN .258 .016 17 8
 EGLN2 Shore .348 .003 80 42
“All P value” and “Rare P value” are the association P values from the test of whether the set of all variants or rare variants (minor allele frequency < 0.01) that 
overlap with the specified genomic feature within the given gene is associated with smoking. “All vars.” and “Rare vars.” is the number of variants included in the 
tested set. “Gene” indicates that the name of the gene the variant set falls within the boundary of as defined by RefSeq. “Feature” describes genomic attributes under 
consideration. “Conserved” indicates regions of high conservation across eutherian mammals; “Exon” designates overlap with RefSeq genes; “Missense” indicates the 
SNV is a missense mutation which results in an amino acid change; “Promoter” indicates the SNV is within 5kb of a transcription start site of the given gene; “Non 
Coding RNA” indicates a functional RNA molecule that is not translated into a protein; “Shore” is ± 2kb flanking a CpG Island; “Synonymous” indicates the variant 
is a coding single-nucleotide polymorphism that does not change the protein sequence; “TFBSCons” indicates SNV is within 100bp of a conserved transcription factor 
recognition sequence in mammals (TRANSFAC, [Matys et al., 2006]). “POLYPHEN—Deleterious” indicates that the variant is predicted to cause a deleterious amino 
acid substitution by PolyPhen2 19; “SIFT—Damaging” indicates that the variant is predicted to cause an amino acid substitution that is likely damaging to protein 
function by SIFT 18. Chromatin states are indicated by the following format: chromatin state name—brain region of chromatin state set. Possible chromatin states are 
Active transcription start site (TSS), Flanking active TSS, Transcription at gene 5′ and 3′, Strong transcription, Weak transcription, Genic Enhancer, Enhancer, ZNF 
genes and repeats, Heterochromatin, Bivalent\Poised TSS, Flanking Bivalent TSS/Enhancer, Bivalent Enhancer, Repressed Polycomb, Weak Repressed Polycomb, and 
Quiescent. The brain regions examined for chromatin states were: AC—anterior caudate, HM—hippocampus, MFL—mid-frontal lobe, and SN—substantia nigra. 
Multiple brain regions listed in a single line indicate that the same set of variants formed the set for all listed brain region, hence the results are the same for these sets.
631Nicotine & Tobacco Research, 2016, Vol. 18, No. 5
Supplementary Material
Supplementary Material and Tables S1–S4 can be found online at 
http://www.ntr.oxfordjournals.org
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